Stephen Holland

Prior to joining Crowell, Stephen served in senior policy roles in the U.S. House of Representatives for over 10 years. Most recently, Stephen spent five years on the Energy and Commerce Committee staff under the leadership of Ranking Member and former Chairman Frank Pallone of New Jersey.  On the Committee staff, he was responsible for legislative action related to numerous agencies and programs, including the FDA, the Biomedical Advanced Research and Development Authority (BARDA), and the 340B drug program. Notably, his work on the Committee included leading negotiations and drafting of the Food and Drug Omnibus Reform Act of 2022 (FDORA), a package of more than 50 policies to expand research, development, and innovation for drugs, medical devices, and personal care products. During the COVID-19 response, Stephen worked to secure billions of dollars for research, development, distribution, and promotion of vaccines, treatment, and diagnostic tests in the CARES Act, the Fiscal Year 2021 Omnibus, and the American Rescue Plan Act.

Stephen also served as Counsel in the Office of Representative Kurt Schrader. There, he led efforts to create the Competitive Genetic Therapy pathway at FDA in the FDA Reauthorization Act of 2017 (FDARA), which has reduced costs for consumers by incentivizing market entry and expediting the development and review of generic drugs where little or no competition existed before.